Cargando…

Modeling and predicting optimal treatment scheduling between the antiangiogenic drug sunitinib and irinotecan in preclinical settings

We present a system of nonlinear ordinary differential equations used to quantify the complex dynamics of the interactions between tumor growth, vasculature generation, and antiangiogenic treatment. The primary dataset consists of longitudinal tumor size measurements (1,371 total observations) in 10...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wilson, S, Tod, M, Ouerdani, A, Emde, A, Yarden, Y, Adda Berkane, A, Kassour, S, Wei, MX, Freyer, G, You, B, Grenier, E, Ribba, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2015
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4759705/ https://www.ncbi.nlm.nih.gov/pubmed/26904386 http://dx.doi.org/10.1002/psp4.12045

Ejemplares similares

Preclinical Modeling of Tumor Growth and Angiogenesis Inhibition to Describe Pazopanib Clinical Effects in Renal Cell Carcinoma
por: Ouerdani, A, et al.
Publicado: (2015)

Sunitinib: the antiangiogenic effects and beyond
por: Hao, Zhonglin, et al.
Publicado: (2016)

Modeling Longitudinal Preclinical Tumor Size Data to Identify Transient Dynamics in Tumor Response to Antiangiogenic Drugs
por: Hutchinson, LG, et al.
Publicado: (2016)

Antiangiogenic cancer drug sunitinib exhibits unexpected proangiogenic effects on endothelial cells
por: Norton, Kerri-Ann, et al.
Publicado: (2014)

Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
por: Bocci, G, et al.
Publicado: (2008)

Preclinical Evaluation of Discorhabdins in Antiangiogenic and Antitumor Models
por: Harris, Emily M., et al.
Publicado: (2018)

Augmenting Experimental Gastric Cancer Activity of Irinotecan through Liposomal Formulation and Antiangiogenic Combination Therapy
por: Awasthi, Niranjan, et al.
Publicado: (2022)

Antiangiogenic Therapy Using Sunitinib Combined with Rapamycin Retards Tumor Growth But Promotes Metastasis()
por: Yin, Tao, et al.
Publicado: (2014)

A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours
por: Boven, E, et al.
Publicado: (2010)

The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer
por: Powles, Thomas, et al.
Publicado: (2008)

Schedule-Dependent Antiangiogenic and Cytotoxic Effects of Chemotherapy on Vascular Endothelial and Retinoblastoma Cells
por: Winter, Ursula, et al.
Publicado: (2016)

Comparison of dynamic contrast-enhanced MR, ultrasound and optical imaging modalities to evaluate the antiangiogenic effect of PF-03084014 and sunitinib
por: Zhang, Cathy C, et al.
Publicado: (2014)

Continuous or intermittent? On the dosing schedule of sunitinib for advanced renal cell carcinoma
por: Nozawa, Masahiro, et al.
Publicado: (2012)

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients
por: Ordu, Çetin, et al.
Publicado: (2016)

Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence
por: Kloth, Jacqueline S. L., et al.
Publicado: (2015)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Tolerability of Alternative Dosing Schedules for Sunitinib: A Systematic Review and Meta-Analysis
por: Kang, Hee Jung, et al.
Publicado: (2020)

The Impact of Modifying Sunitinib Treatment Scheduling on Renal Cancer Tumor Biology and Resistance
por: Lin, Harrison Sicheng, et al.
Publicado: (2022)

Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
por: Huang, Jiao-Ren, et al.
Publicado: (2019)

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
por: Kleibeuker, Esther A, et al.
Publicado: (2015)

A meta-analysis of threats to valid clinical inference in preclinical research of sunitinib
por: Henderson, Valerie C, et al.
Publicado: (2015)

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Sunitinib in Metastatic Renal Cell Carcinoma: The Pharmacological Basis of the Alternative 2/1 Schedule
por: Di Paolo, Antonello, et al.
Publicado: (2017)

Targeted antiangiogenic agents in combination with cytotoxic chemotherapy in preclinical and clinical studies in sarcoma
por: Vo, Kieuhoa T., et al.
Publicado: (2016)

A preclinical evaluation of pemetrexed and irinotecan combination as second-line chemotherapy in pancreatic cancer
por: Mercalli, A, et al.
Publicado: (2007)

Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours
por: SAPONARA, MARISTELLA, et al.
Publicado: (2014)

Results of weekday-on and weekend-off administration schedule of sunitinib therapy for advanced renal cell carcinoma
por: Kawashima, Atsunari, et al.
Publicado: (2018)

Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma
por: Zhu, Xudong, et al.
Publicado: (2021)

Preclinical Synergistic Combination Therapy of Lurbinectedin with Irinotecan and 5-Fluorouracil in Pancreatic Cancer
por: Tummala, Tej, et al.
Publicado: (2023)

Three-week schedule of irinotecan plus cisplatin in patients with previously untreated extensive-stage small-cell lung cancer
por: Hong, Y S, et al.
Publicado: (2006)

The Tyrosine Kinase Inhibitor Sunitinib Affects Ovulation but Not Ovarian Reserve in Mouse: A Preclinical Study
por: Bernard, Valérie, et al.
Publicado: (2016)

Antiangiogenic Properties of Axitinib versus Sorafenib Following Sunitinib Resistance in Human Endothelial Cells—A View towards Second Line Renal Cell Carcinoma Treatment
por: Juengel, Eva, et al.
Publicado: (2021)

ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer
por: Davis, S. Lindsey, et al.
Publicado: (2022)

Modifying sunitinib schedule in advanced kidney cancer patients: Reflections from the results of the renal EFFECT trial
por: Porta, Camillo, et al.
Publicado: (2012)

Second-line sunitinib for Chinese patients with advanced gastrointestinal stromal tumor: 37.5 mg schedule outperformed 50 mg schedule in adherence and prognosis
por: Zhang, Chenli, et al.
Publicado: (2021)

Seconds-resolved pharmacokinetic measurements of the chemotherapeutic irinotecan in situ in the living body
por: Idili, Andrea, et al.
Publicado: (2019)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Tolerability and outcome of sunitinib by giving 4/2 schedule versus 2/1 schedule in metastatic renal cell carcinoma patients: a prospective randomized multi-centric Egyptian study
por: Abdelaziz, Lobna A., et al.
Publicado: (2021)

A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
por: Schoemaker, N E, et al.
Publicado: (2004)

CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer
por: Devapatla, Bharat, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p9laugfc4iu5rp1eq46nnl8pqm